Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: the COSMEX Study.
Clinical Therapeutics(2019)
摘要
This study indicates that long-term mepolizumab treatment is well tolerated and associated with sustained clinical benefits in patients with severe eosinophilic asthma. ClinicalTrials.gov identifier: NCT02135692.
更多查看译文
关键词
asthma exacerbations,corticosteroids,long-term safety,mepolizumab,severe eosinophilic asthma
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络